Carcinoembryonic antigen

Last updated
Carcinoembryonic antigen
PBB Protein CEACAM5 image.jpg
Structure of extracellular domains of CEACAM based on 1e07 [1]
Identifiers
SymbolCEACAM
Membranome 211

Carcinoembryonic antigen (CEA) describes a set of highly-related glycoproteins involved in cell adhesion. CEA is normally produced in gastrointestinal tissue during fetal development, but the production stops before birth. Consequently, CEA is usually present at very low levels in the blood of healthy adults (about 2–4 ng/mL). [2] However, the serum levels are raised in some types of cancer, which means that it can be used as a tumor marker in clinical tests. Serum levels can also be elevated in heavy smokers. [3]

Contents

CEA are glycosyl phosphatidyl inositol (GPI) cell-surface-anchored glycoproteins whose specialized sialo fucosylated glycoforms serve as functional colon carcinoma L-selectin and E-selectin ligands, which may be critical to the metastatic dissemination of colon carcinoma cells. [4] [5] [6] Immunologically they are characterized as members of the CD66 cluster of differentiation. The proteins include CD66a, CD66b, CD66c, CD66d, CD66e, CD66f.

History

CEA was first identified in 1965 by Phil Gold,a Canadian physician, scientist and professor and Samuel O. Freedman who is also a Canadian professor of immunology in human colon cancer tissue extracts. [7]

Diagnostic significance

The CEA blood test is not reliable for diagnosing cancer or as a screening test for early detection of cancer. [8] Most types of cancer do not result in a high CEA level. [9]

Serum from individuals with colorectal carcinoma often has higher levels of CEA than healthy individuals (above approximately 2.5ng/mL). [10] CEA measurement is mainly used as a tumor marker to monitor colorectal carcinoma treatment, to identify recurrences after surgical resection, for staging or to localize cancer spread through measurement of biological fluids. [11] CEA levels may also be raised in gastric carcinoma, pancreatic carcinoma, lung carcinoma, breast carcinoma, and medullary thyroid carcinoma, as well as some non-neoplastic conditions like ulcerative colitis, pancreatitis, cirrhosis, [12] COPD, Crohn's disease, hypothyroidism [13] as well as in smokers. [14] Elevated CEA levels should return to normal after successful surgical removal of the tumor and can be used in follow up, especially of colorectal cancers. [15]

CEA elevation is known to be affected by multiple factors. It varies inversely with tumor grade; well-differentiated tumors secrete more CEA. CEA is elevated more in tumors with lymph node and distant metastasis than in organ-confined tumors and, thus, varies directly with tumor stage. Left-sided tumors generally tend to have higher CEA levels than right-sided tumors. [16] Tumors causing bowel obstruction produce higher CEA levels. [16] Aneuploid tumors produce more CEA than diploid tumors. [17] Liver dysfunction increases CEA levels as the liver is the primary site of CEA metabolism. [3]

Antibodies

Immunohistochemistry using antibodies against CEA in a hepatocellular carcinoma, showing the typical canalicular pattern. Immunohistochemistry for CEA in hepatocellular carcinoma.jpg
Immunohistochemistry using antibodies against CEA in a hepatocellular carcinoma, showing the typical canalicular pattern.

An anti-CEA antibody is an antibody against CEA. Such antibodies to CEA are commonly used in immunohistochemistry to identify cells expressing the glycoprotein in tissue samples. In adults, CEA is primarily expressed in cells of tumors (some malignant, some benign) [19] but they are particularly associated with the adenocarcinomas, such as those arising in the colon, lung, breast, stomach, or pancreas. It can therefore be used to distinguish between these and other similar cancers. For example, it can help to distinguish between adenocarcinoma of the lung and mesothelioma, a different type of lung cancer which is not normally CEA positive. Because even monoclonal antibodies to CEA tend to have some degree of cross-reactivity, occasionally giving false positive results, it is commonly employed in combination with other immunohistochemistry tests, such as those for BerEp4, WT1, and calretinin. [20] For cancers that highly express CEA, targeting CEA through radioimmunotherapy is one of the therapy approaches. [21] Engineered antibodies such as single-chain Fv antibodies (sFvs) or bispecific antibodies have been used for targeting and therapy of CEA expressing tumors both in vitro and in vivo with promising results [22] [23] Regions of high CEA levels in the body can be detected with the monoclonal antibody arcitumomab. [24]

Genetics

CEA and related genes make up the CEA family belonging to the immunoglobulin superfamily.

In humans, the carcinoembryonic antigen family consists of 29 genes, 18 of which are normally expressed. [25] The following is a list of human genes which encode carcinoembryonic antigen-related cell adhesion proteins: CEACAM1, CEACAM3, CEACAM4, CEACAM5, CEACAM6, CEACAM7, CEACAM8, CEACAM16, CEACAM18, CEACAM19, CEACAM20, CEACAM21

See also

Related Research Articles

<span class="mw-page-title-main">Adenocarcinoma</span> Medical condition

Adenocarcinoma is a type of cancerous tumor that can occur in several parts of the body. It is defined as neoplasia of epithelial tissue that has glandular origin, glandular characteristics, or both. Adenocarcinomas are part of the larger grouping of carcinomas, but are also sometimes called by more precise terms omitting the word, where these exist. Thus invasive ductal carcinoma, the most common form of breast cancer, is adenocarcinoma but does not use the term in its name—however, esophageal adenocarcinoma does to distinguish it from the other common type of esophageal cancer, esophageal squamous cell carcinoma. Several of the most common forms of cancer are adenocarcinomas, and the various sorts of adenocarcinoma vary greatly in all their aspects, so that few useful generalizations can be made about them.

<span class="mw-page-title-main">Keratin 20</span> Protein-coding gene in the species Homo sapiens

Keratin 20, often abbreviated CK20, is a protein that in humans is encoded by the KRT20 gene.

<span class="mw-page-title-main">Immunohistochemistry</span> Common application of immunostaining

Immunohistochemistry (IHC) is a form of immunostaining. It involves the process of selectively identifying antigens (proteins) in cells and tissue, by exploiting the principle of antibodies binding specifically to antigens in biological tissues. Albert Hewett Coons, Ernest Berliner, Norman Jones and Hugh J Creech was the first to develop immunofluorescence in 1941. This led to the later development of immunohistochemistry.

A tumor marker is a biomarker that can be used to indicate the presence of cancer or the behavior of cancers. They can be found in bodily fluids or tissue. Markers can help with assessing prognosis, surveilling patients after surgical removal of tumors, and even predicting drug-response and monitor therapy.

<span class="mw-page-title-main">Selectin</span> Family of cell adhesion molecules

The selectins are a family of cell adhesion molecules. All selectins are single-chain transmembrane glycoproteins that share similar properties to C-type lectins due to a related amino terminus and calcium-dependent binding. Selectins bind to sugar moieties and so are considered to be a type of lectin, cell adhesion proteins that bind sugar polymers.

<span class="mw-page-title-main">CD44</span> Cell-surface glycoprotein

The CD44 antigen is a cell-surface glycoprotein involved in cell–cell interactions, cell adhesion and migration. In humans, the CD44 antigen is encoded by the CD44 gene on chromosome 11. CD44 has been referred to as HCAM, Pgp-1, Hermes antigen, lymphocyte homing receptor, ECM-III, and HUTCH-1.

Tumor M2-PK is a synonym for the dimeric form of the pyruvate kinase isoenzyme type M2 (PKM2), a key enzyme within tumor metabolism. Tumor M2-PK can be elevated in many tumor types, rather than being an organ-specific tumor marker such as PSA. Increased stool (fecal) levels are being investigated as a method of screening for colorectal tumors, and EDTA plasma levels are undergoing testing for possible application in the follow-up of various cancers.

Technetium (99mTc) arcitumomab is a drug used for the diagnostic imaging of colorectal cancers, marketed by Immunomedics. It consists of the Fab' fragment of a monoclonal antibody and a radionuclide, technetium-99m.

<span class="mw-page-title-main">CA19-9</span> Chemical compound

Carbohydrate antigen 19-9 (CA19-9), also known as sialyl-LewisA, is a tetrasaccharide which is usually attached to O-glycans on the surface of cells. It is known to play a role in cell-to-cell recognition processes. It is also a tumor marker used primarily in the management of pancreatic cancer.

<span class="mw-page-title-main">Mesothelin</span> Protein found in humans

Mesothelin, also known as MSLN, is a protein that in humans is encoded by the MSLN gene.

Podocalyxin, a sialoglycoprotein, is thought to be the major constituent of the glycocalyx of podocytes in the glomerulus in the kidneys. It is a member of the CD34 family of transmembrane sialomucins. It coats the secondary foot processes of the podocytes. It is negatively charged and thus functions through charge repulsion to keep adjacent foot processes separated, thereby keeping the urinary filtration barrier open. This function is further supported by knockout studies in mice which reveal an essential role in podocyte morphogenesis and a role in the opening of vascular lumens and regulation of vascular permeability. Of note, this is the only cell surface sialomucin knockout known to display a lethal phenotype.

<span class="mw-page-title-main">CEACAM1</span> Mammalian protein found in Homo sapiens

Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) also known as CD66a, is a human glycoprotein, and a member of the carcinoembryonic antigen (CEA) gene family.

<span class="mw-page-title-main">Epithelial cell adhesion molecule</span> Transmembrane glycoprotein

Epithelial cell adhesion molecule (EpCAM), also known as CD326 among other names, is a transmembrane glycoprotein mediating Ca2+-independent homotypic cell–cell adhesion in epithelia. EpCAM is also involved in cell signaling, migration, proliferation, and differentiation. Additionally, EpCAM has oncogenic potential via its capacity to upregulate c-myc, e-fabp, and cyclins A & E. Since EpCAM is expressed exclusively in epithelia and epithelial-derived neoplasms, EpCAM can be used as diagnostic marker for various cancers. It appears to play a role in tumorigenesis and metastasis of carcinomas, so it can also act as a potential prognostic marker and as a potential target for immunotherapeutic strategies.

<span class="mw-page-title-main">CEACAM6</span> Mammalian protein found in Homo sapiens

Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) also known as CD66c, is a member of the carcinoembryonic antigen (CEA) gene family..

<span class="mw-page-title-main">Medullary thyroid cancer</span> Malignant thyroid neoplasm originating from C-cells

Medullary thyroid cancer is a form of thyroid carcinoma which originates from the parafollicular cells, which produce the hormone calcitonin. Medullary tumors are the third most common of all thyroid cancers and together make up about 3% of all thyroid cancer cases. MTC was first characterized in 1959.

<span class="mw-page-title-main">TPBG</span> Human protein

Trophoblast glycoprotein, also known as TPBG, 5T4, Wnt-Activated Inhibitory Factor 1 or WAIF1, is a human protein encoded by a TPBG gene. TPBG is an antagonist of Wnt/β-catenin signalling pathway.

Tumor-associated glycoprotein 72 (TAG-72) is a glycoprotein found on the surface of many cancer cells, including ovary, breast, colon, lung, and pancreatic cancers. It is a mucin-like molecule with a molar mass of over 1000 kDa.

<span class="mw-page-title-main">Galectin-4</span> Protein-coding gene in the species Homo sapiens

Galectin-4 is a protein that in humans is encoded by the LGALS4 gene.

<span class="mw-page-title-main">CEACAM5</span> Mammalian protein found in Homo sapiens

Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also known as CD66e, is a member of the carcinoembryonic antigen (CEA) gene family.

CA 242 is a tumor marker for sialylated Lewis carbohydrates associated with adenocarcinomas and e-selectin-mediated metastatic risk. It is commonly tested along with CEA, CA19-9, and CA242 for detecting pancreatic cancer. The specificity of CA 242 is higher than similar markers. Current research dictates that diagnostic efficiency is highest when various tumor markers are tested for at once.

References

  1. ↑ Boehm MK, Perkins SJ (June 2000). "Structural models for carcinoembryonic antigen and its complex with the single-chain Fv antibody molecule MFE23". FEBS Letters. 475 (1): 11–6. doi:10.1016/S0014-5793(00)01612-4. PMID   10854848. S2CID   5765612.
  2. ↑ Gan N, Jia L, Zheng L (2011-10-28). "A sandwich electrochemical immunosensor using magnetic DNA nanoprobes for carcinoembryonic antigen". International Journal of Molecular Sciences. 12 (11): 7410–23. doi: 10.3390/ijms12117410 . PMC   3233412 . PMID   22174606.
  3. 1 2 Duffy MJ (April 2001). "Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?". Clinical Chemistry. 47 (4): 624–30. doi: 10.1093/clinchem/47.4.624 . PMID   11274010.
  4. ↑ Thomas SN, Zhu F, Schnaar RL, Alves CS, Konstantopoulos K (June 2008). "Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow". The Journal of Biological Chemistry. 283 (23): 15647–55. doi: 10.1074/jbc.M800543200 . PMC   2414264 . PMID   18375392.
  5. ↑ Konstantopoulos K, Thomas SN (2009). "Cancer cells in transit: the vascular interactions of tumor cells". Annual Review of Biomedical Engineering. 11: 177–202. doi: 10.1146/annurev-bioeng-061008-124949 . PMID   19413512.
  6. ↑ Thomas SN, Tong Z, Stebe KJ, Konstantopoulos K (2009). "Identification, characterization and utilization of tumor cell selectin ligands in the design of colon cancer diagnostics". Biorheology. 46 (3): 207–25. doi:10.3233/BIR-2009-0534. PMID   19581728.
  7. ↑ Gold P, Freedman SO (March 1965). "Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques". The Journal of Experimental Medicine. 121 (3): 439–62. doi:10.1084/jem.121.3.439. PMC   2137957 . PMID   14270243.
  8. ↑ Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C, Topolcan O (April 2003). "Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines". European Journal of Cancer. 39 (6): 718–27. doi:10.1016/S0959-8049(02)00811-0. PMID   12651195.
  9. ↑ Asad-Ur-Rahman F, Saif MW (June 2016). "Elevated Level of Serum Carcinoembryonic Antigen (CEA) and Search for a Malignancy: A Case Report". Cureus. 8 (6): e648. doi: 10.7759/cureus.648 . PMC   4954749 . PMID   27446768.
  10. ↑ Ballesta AM, Molina R, Filella X, Jo J, Giménez N (1995). "Carcinoembryonic antigen in staging and follow-up of patients with solid tumors". Tumour Biology. 16 (1): 32–41. doi:10.1159/000217926. PMID   7863220.
  11. ↑ Duffy MJ (April 2001). "Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?". Clinical Chemistry. 47 (4): 624–30. doi: 10.1093/clinchem/47.4.624 . PMID   11274010.
  12. ↑ Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA (January 1998). "The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA". Annals of Clinical Biochemistry. 35 ( Pt 1) (1): 99–103. doi:10.1177/000456329803500113. PMID   9463746. S2CID   39789615.
  13. ↑ De Mais D (2009). ASCP Quick Compendium of Clinical Pathology (2nd ed.). ASCP Press. ISBN   978-0-89189-567-1.
  14. ↑ Sajid KM, Parveen R, Durr-e-Sabih, Chaouachi K, Naeem A, Mahmood R, Shamim R (December 2007). "Carcinoembryonic antigen (CEA) levels in hookah smokers, cigarette smokers and non-smokers". The Journal of the Pakistan Medical Association. 57 (12): 595–9. PMID   18173042.
  15. ↑ Goldstein MJ, Mitchell EP (2005). "Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer". Cancer Investigation. 23 (4): 338–51. doi:10.1081/CNV-58878. PMID   16100946. S2CID   27100764.
  16. 1 2 "Carcinoembryonic Antigen (CEA) Exeter Clinical Laboratory International". www.exeterlaboratory.com. Retrieved 2023-10-13.
  17. ↑ Rodriguez-Bigas, Miguel A.; Lin, Edward H.; Crane, Christopher H. (2003), "Tumor Markers", Holland-Frei Cancer Medicine. 6th edition, BC Decker, retrieved 2023-10-13
  18. ↑ Machado-Netto MC, Lacerda EC, Heinke T, Maia DC, Lowen MS, Saad ED (2006). "Massive orbital metastasis of hepatocellular carcinoma". Clinics (Sao Paulo). 61 (4): 359–62. doi: 10.1590/s1807-59322006000400015 . PMID   16924330.{{cite journal}}: CS1 maint: multiple names: authors list (link)
    "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0)"
  19. ↑ Kankanala, Vijaya L.; Mukkamalla, Shiva Kumar R. (2023), "Carcinoembryonic Antigen", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID   35201700 , retrieved 2023-10-13
  20. ↑ Leong AS, Cooper K, Leong FJ (2003). Manual of Diagnostic Cytology (2ND ed.). Greenwich Medical Media, Ltd. pp. 51–52. ISBN   978-1-84110-100-2.
  21. ↑ Wong, JY; Chu, DZ; Williams, LE; Liu, A; Zhan, J; Yamauchi, DM; Wilczynski, S; Wu, AM; Yazaki, PJ; Shively, JE; Leong, L; Raubitschek, AA (April 2006). "A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies". Cancer Biotherapy & Radiopharmaceuticals. 21 (2): 88–100. doi:10.1089/cbr.2006.21.88. PMID   16706629.
  22. ↑ Chester, Kerry A.; Mayer, Astrid; Bhatia, Jeetendra; Robson, Lynda; Spencer, Daniel I. R.; Cooke, Stephen P.; Flynn, Aiden A.; Sharma, Surinder K.; Boxer, Geoffery; Pedley, R. Barbara; Begent, Richard H. J. (19 July 2000). "Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer". Cancer Chemotherapy and Pharmacology. 46 (S1): S8–S12. doi:10.1007/PL00014055. PMID   10950140. S2CID   2199095.
  23. ↑ Bacac, Marina; Fauti, Tanja; Sam, Johannes; Colombetti, Sara; Weinzierl, Tina; Ouaret, Djamila; Bodmer, Walter; Lehmann, Steffi; Hofer, Thomas; Hosse, Ralf J.; Moessner, Ekkehard; Ast, Oliver; Bruenker, Peter; Grau-Richards, Sandra; Schaller, Teilo; Seidl, Annette; Gerdes, Christian; Perro, Mario; Nicolini, Valeria; Steinhoff, Nathalie; Dudal, Sherri; Neumann, Sebastian; von Hirschheydt, Thomas; Jaeger, Christiane; Saro, Jose; Karanikas, Vaios; Klein, Christian; Umaña, Pablo (1 July 2016). "A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors". Clinical Cancer Research. 22 (13): 3286–3297. doi: 10.1158/1078-0432.CCR-15-1696 . PMID   26861458. S2CID   2605514.
  24. ↑ Cheng KT (2013). "99mTc-Arcitumomab". Molecular Imaging and Contrast Agent Database (MICAD). Bethesda (MD): National Center for Biotechnology Information (US).
  25. ↑ Hammarström S (April 1999). "The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues". Seminars in Cancer Biology. 9 (2): 67–81. doi:10.1006/scbi.1998.0119. PMID   10202129.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.